FTCM
MRTX

First Trust Capital Management’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

First Trust Capital Management’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-41,231
Closed -$2.42M – 160
2023
Q4 		$2.42M Buy
+41,231
New +$2.32M 0.19% 100

Other funds holding MRTX

S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

First Trust Capital Management's MRTX Position: Q1 2024 in Review

First Trust Capital Management sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 41,231 shares — an estimated $2.42M sold.

First Trust Capital Management first reported a position in MRTX in Q4 2023 and held it in 1 quarter. The position peaked at $2.42M in Q4 2023. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.

  • First Trust Capital Management reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • First Trust Capital Management sold 41,231 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $2.42M.
  • First Trust Capital Management first reported a position in Mirati Therapeutics, Inc. Common Stock in Q4 2023 and held it in 1 quarter.
  • First Trust Capital Management's Mirati Therapeutics, Inc. Common Stock position peaked at $2.42M in Q4 2023.
  • 2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.

Based on First Trust Capital Management's 13F filing for Q1 2024, filed 15 May 2024.